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A B S T R A C T
The KCNH2 or human ether-a go-go-related gene (hERG) encodes the Kv11.1 potassium channel that conducts
the rapidly activating delayed rectifier potassium current in the heart. The expression of Kv11.1 C-terminal
isoforms is directed by the alternative splicing and polyadenylation of intron 9. Splicing of intron 9 leads to the
formation of a functional, full-length Kv11.1a isoform and polyadenylation of intron 9 results in the production
of a non-functional, C-terminally truncated Kv11.1a-USO isoform. The relative expression of Kv11.1a and
Kv11.1a-USO plays an important role in regulating Kv11.1 channel function. In the heart, only one-third of
KCNH2 pre-mRNA is processed to Kv11.1a due to the weak 5′ splice site of intron 9. We previously showed that
the weak 5′ splice site is caused by sequence deviation from the consensus, and that mutations toward the
consensus sequence increased the efficiency of intron 9 splicing. It is well established that 5′ splice sites are
recognized by complementary base-paring with U1 small nuclear RNA (U1 snRNA). In this study, we modified
the sequence of U1 snRNA to increase its complementarity to the 5′ splice site of KCNH2 intron 9 and observed a
significant increase in the efficiency of intron 9 splicing. RNase protection assay and western blot analysis
showed that modified U1 snRNA increased the expression of the functional Kv11.1a isoform and concomitantly
decreased the expression of the non-functional Kv11.1a-USO isoform. In patch-clamp experiments, modified U1
snRNA significantly increased Kv11.1 current. Our findings suggest that relative expression of Kv11.1 C-terminal
isoforms can be regulated by modified U1 snRNA.
1. Introduction
KCNH2 or human ether-à-go-go-related gene (hERG) encodes the
Kv11.1 potassium channel that conducts the rapidly activating delayed
rectifier K+ current (IKr) in the heart. (Warmke and Ganetzky, 1994;
Sanguinetti et al., 1995; Trudeau et al., 1995; Zhou et al., 1998). Mu-
tations in KCNH2 cause long QT syndrome type 2 (LQT2) (Curran et al.,
1995). Several Kv11.1 isoforms, Kv11.1a, Kv11.1b, Kv11.1a-USO and
Kv11.1b-USO, have been identified (Larsen, 2010). The Kv11.1a iso-
form represents the full-length Kv11.1 channel consisting of 1159
amino acids. Kv11.1b lacks the first 376 amino acids of Kv11.1a and has
an alternate 36 amino acid N-terminus. The C-terminal isoforms
Kv11.1a-USO and Kv11.1b-USO contain the truncated USO C-terminus,
in which the last 359 amino acids of Kv11.1a/b are replaced by an
alternate 88 residue C-terminal end (Larsen, 2010). Functional studies
have shown that Kv11.1a and Kv11.1b isoforms generate Kv11.1 cur-
rents with distinct gating properties (Sanguinetti et al., 1995; Trudeau
et al., 1995; Lees-Miller et al., 1997; London et al., 1997; Zhou et al.,
1998), whereas the Kv11.1a-USO and Kv11.1b-USO isoforms fail to
form functional channels when expressed in mammalian cells
(Kupershmidt et al., 1998; Guasti et al., 2008; Gong et al., 2010; Stump
et al., 2012). Coexpression of Kv11.1a and Kv11.1a-USO in equimolar
concentrations has no obvious effect on Kv11.1 current (Kupershmidt
et al., 1998). When an excess of Kv11.1a-USO or Kv11.1b-USO is co-
expressed with Kv11.1a or Kv11.1b, a decrease in Kv11.1 current is
observed (Kupershmidt et al., 1998; Guasti et al., 2008).
We have previously shown that Kv11.1a and Kv11.1a-USO are
produced from a single KCNH2 pre-mRNA precursor by use of alter-
native splicing and alternative polyadenylation sites (Gong et al.,
2010). Kv11.1a is produced by the splicing of intron 9 and poly-
adenylation at a distal poly(A) site in exon 15, whereas Kv11.1a-USO is
generated by the silencing of the 5′ splice site of intron 9 and poly-
adenylation at an intronic poly(A) site in intron 9. Because formation of
Kv11.1a and Kv11.1a-USO is mutually exclusive, the expression of one
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C-terminal isoform is generated at the expense of the other C-terminal
isoform. The importance of alternative splicing and alternative poly-
adenylation of KCNH2 pre-mRNA in regulation of Kv11.1 isoform ex-
pression is underscored by our recent finding that the disease-causing
KCNH2 mutation IVS9-2delA disrupted normal splicing and resulted in
exclusive polyadenylation of intron 9, leading to the switch from the
functional Kv11.1a isoform to the non-functional Kv11.1a-USO isoform
(Gong et al., 2014a). Thus, the relative expression of the C-terminal
isoforms plays an important role in regulation of Kv11.1 channel
function as well as in the pathogenesis of long QT syndrome.
The splicing of KCNH2 intron 9 is inefficient as only one-third of
KCNH2 pre-mRNA is processed to Kv11.1a in the heart (Kupershmidt
et al., 1998; Gong et al., 2010). We previously showed that the in-
efficient splicing of intron 9 is due to the presence of a weak 5′ splice
site, which deviates from the consensus sequence at four positions
(Gong et al., 2010). The initial step of splicing involves the recognition
of the 5′ splice site by the U1 small nuclear ribonucleoprotein, which is
mediated by base-pair complementarity with its RNA component the
U1 small nuclear RNA (U1 snRNA) (Zhuang and Weiner, 1986). It is
likely that deviation of the 5′ splice site of KCNH2 intron 9 from the
consensus sequence reduces its base-pair complementarity to U1
snRNA, thereby leading to inefficient intron 9 splicing. In the present
study, we tested the hypothesis that increasing U1 snRNA com-
plementarity to the 5′ splice site of KCNH2 intron 9 would enhance the
efficiency of intron 9 splicing and shift the alternative processing of
KCNH2 pre-mRNA toward the production of the Kv11.1a isoform. Our
findings indicate that the expression of the functional Kv11.1a isoform
can be upregulated by modified U1 snRNA.
2. Methods
2.1. Plasmid constructs and transfection
The minigene luciferase reporter construct was generated by sub-
cloning the Renilla luciferase gene downstream of a splicing competent
KCNH2 minigene, as previously described (Gong et al., 2014b). The
expression of the minigene luciferase reporter is driven by a CMV
promoter (Fig. 1A). The vector also contains the firefly luciferase gene
driven by the SV40 promoter, which was used as a control for trans-
fection efficiency. HEK293 cells were transiently transfected with the
minigene luciferase reporter construct using the Effectene method
(Qiagen, Valencia, CA). After 24 h, cells were harvested and assayed for
both firefly and Renilla luciferase activity using the Dual-Luciferase
assay kit (Promega, Madison, WI). Data were analyzed by normalizing
Renilla luciferase activity to firefly luciferase activity.
The generation of the full-length KCNH2 splicing-competent con-
struct composed of Kv11.1a cDNA from exon 1 to exon 6 and the
KCNH2 genomic DNA from intron 6 to poly(A) site was described
previously (Gong et al., 2010). The full-length KCNH2 splicing-com-
petent construct was subcloned into a modified pcDNA5 vector, in
which the BGH poly(A) signal was deleted. Stably transfected Flp-In CV-
1 cells were generated by the cotransfection of the full-length KCHN2
splicing-competent construct (0.1 μg) with the Flp recombinase ex-
pression vector pOG44 (0.9 μg) using the Effectene method and selected
with 100 μg/ml hygromycin.
2.2. Construction of U1 snRNA recombinant adenovirus
The U1 snRNA construct in the pUC13 vector was generously pro-
vided by Dr. Alan Weiner from University of Washington. Modification
of U1 snRNA at position 3 and 5 was performed by PCR. The AdEasy
vector kit was used to generate WT and modified U1 snRNA re-
combinant adenoviruses (Stratagene, La Jolla, CA). First, the WT and
modified U1 snRNA were subcloned into pShuttle vector and re-
combined with the pAdEasy plasmid in E. coli strain BJ5183. The
pAdEasy/U1 snRNA plasmids were transfected into HEK293 cells. After
2 days, the transfected cells were cultured in growth medium con-
taining 1.25% SeaPlaque-agarose (Lonza, Rockland, MD) to promote
the formation of recombinant viral plaques. Approximately three weeks
following transfection, individual plaques were picked, amplified in
HEK293 cells, and purified over a discontinuous CsCl gradient (Gong
et al., 2007).
2.3. RNase protection assay
RNA isolation and the RNase protection assay (RPA) were per-
formed as previously described (Gong et al., 2010). Briefly, antisense
RNA riboprobes were transcribed in vitro in the presence of biotin-14-
CTP. Yeast RNA was used as a control for the complete digestion of the
probes by RNase. The relative intensity of each band was quantified
using ImageJ software and adjusted for the number of biotin-labeled
cytidines in each protected fragment. The expression level of the hy-
gromycin B resistance gene from the KCNH2 gene constructs was used
to normalize relative expression of Kv11.1 isoforms.
2.4. Immunoblot analysis
Immunoblot analysis was performed as previously described (Gong
et al., 2010). The cell lysates were subjected to SDS-polyacrylamide gel
electrophoresis and then electrophoretically transferred onto ni-
trocellulose membranes. The membranes were incubated with an anti-
Kv11.1 antibody against the N-terminus of Kv11.1a and Kv11.1a-USO
proteins (H-175, Santa Cruz, Santa Cruz, CA) at a 1:600 dilution and
visualized with the ECL detection kit (Amersham, Piscataway, NJ). The
Fig. 1. Effect of modified U1 snRNA on splicing
of KCNH2 intron 9 using a luciferase reporter
construct. (A) Diagram of the KCNH2 minigene
luciferase reporter construct. (B) Diagram of the
modified U1 snRNA that increases its com-
plementarity to the 5′ splice site of KCNH2 intron
9 at the +4 and +6 positions. (C) Histogram
showing the effect of modified U1 snRNA on lu-
ciferase activity (n= 6–7, ***P < 0.001).
expression level of hygromycin B phosphotransferase (HPT) encoded by
the hygromycin B resistant gene was used as loading control (Gong
et al., 2010).
2.5. Patch-clamp recordings
Membrane currents were recorded in whole cell configuration using
suction pipettes as previously described (Zhou et al., 1998). The bath
solution contained (in mM) 137 NaCl, 4 KCl, 1.8 CaCl2, 1 MgCl2, 10
glucose, and 10 HEPES (pH 7.4 with NaOH). The pipette solution
contained (in mM) 130 KCl, 1 MgCl2, 5 EGTA, 5 MgATP, and 10 HEPES
(pH 7.2 with KOH). All patch-clamp experiments were performed at
22–23 °C. Kv11.1 current was activated by depolarizing steps between
−70 and +50 mV from a holding potential of−80 mV and Kv11.1 tail
current was recorded following repolarization to −50 mV.
2.6. Statistical analysis
Data are presented as mean ± standard error of mean. Student's t-
test was used for comparison between two groups. ANOVA with
Bonferroni correction was used for comparisons between more than two
groups. P < 0.05 is considered statistically significant.
3. Results
3.1. Splicing of KCNH2 intron 9 can be improved by complementary base
changes in U1 snRNA
We have shown previously that the splicing of KCNH2 intron 9 is
inefficient due to the presence of non-consensus nucleotides at +4 and
+6 positions of the 5′ splice site. When both +4 and +6 nucleotides
are changed to the consensus sequence, the Kv11.1a isoform is ex-
clusively produced (Gong et al., 2010). To test whether the inefficient
splicing of KCNH2 intron 9 is due to base-pair mismatch between U1
snRNA and the 5′ splice site, we changed the U1 snRNA at position 3
(3A>C) or 5 (5U>A) to make them complementary to the +6g or
+4u nt of the 5′ splice site of KCNH2 intron 9 (Fig. 1B), respectively.
We cotransfected the minigene luciferase reporter construct with the
wild-type (WT) or modified U1 snRNA into HEK293 cells. In the
minigene luciferase reporter construct, the splicing of intron 9 would
generate active luciferase and polyadenylation of intron 9 would result
in no luciferase activity (Gong et al., 2014b). As shown in Fig. 1C, co-
transfection with modified U1 snRNA at position 3 (3A>C) or 5
(5U>A) increased the luciferase activity compared to WT U1 snRNA
(P < 0.001). When U1 snRNA was modified at both 3 and 5 positions
(3A>C/5U>A), the luciferase activity was further increased com-
pared to 3A>C or 5U>A alone (P < 0.001). These results demon-
strate that the weak 5′ splice site of KCNH2 intron 9 is due to base-pair
mismatches between U1 snRNA and the 5′ splice site, and that the
splicing efficiency of KCNH2 intron 9 can be increased by com-
plementary base changes in U1 snRNA.
3.2. Regulation of Kv11.1 isoform expression by modified U1 snRNA
To test whether the modified U1 snRNA can regulate the relative
expression of Kv11.1 isoforms, we used the full-length KCNH2 splicing-
competent construct composed of the Kv11.1a cDNA from exon 1 to
exon 6 and the genomic sequence spanning intron 6 to the poly(A)
signal of the KCNH2 gene (Fig. 2A) (Gong et al., 2010). If intron 9 is
spliced and the poly(A) site in exon 15 is used, the full-length Kv11.1a
transcript will be produced. If the transcript is polyadenylated at the
intron 9 poly(A) site, the Kv11.1a-USO isoform will be generated. When
expressed in Flp-In CV-1 cells, the full-length KCNH2 splicing-compe-
tent construct underwent alternative processing to generate the
Kv11.1a and Kv11.1a-USO isoforms. Treatment with modified U1
snRNA (3A>C/5U>A) adenovirus resulted in an increase in the
Kv11.1a transcript and a decrease in the Kv11.1a-USO transcript
compared to the control WT U1 snRNA adenovirus treatment (Fig. 2B,
C, P < 0.01). This result suggests that relative expression of Kv11.1a
and Kv11.1a-USO isoforms can be modulated by a modified U1 snRNA
with increased complementarity to the 5′ splice site of KCNH2 intron 9.
3.3. Upregulation of Kv11.1a channel protein by modified U1 snRNA
To determine whether modified U1 snRNA-induced modulation of
Kv11.1 C-terminal isoform expression leads to the isoform switch at the
protein level, we analyzed Kv11.1 protein expression by immunoblot.
When expressed in Flp-In CV-1 cells, the full-length KCNH2 splicing-
competent construct produced three protein bands at about 155 kDa,
135 kDa and 100 kDa. The 155 kDa band represents the fully glycosy-
lated mature form of Kv11.1a, the 135 kDa band represents the core-
glycosylated immature form of Kv11.1a, and the 100 kDa band re-
presents the core-glycosylated form of Kv11.1a-USO (Gong et al.,
2010). Flp-In CV-1 cells stably expressing the full-length KCNH2 spli-
cing-competent construct were treated with different concentrations of
WT or modified U1 snRNA adenovirus. Treatment with modified U1
snRNA (3A>C/5U>A) significantly increased the level of Kv11.1a
protein (P < 0.001) and decreased the Kv11.1a-USO protein level
compared to WT U1 snRNA control (P < 0.05) (Fig. 3).
3.4. Modified U1 snRNA increased Kv11.1 channel current
To study functional consequence of modified U1 snRNA, we per-
formed patch-clamp recordings of Kv11.1 channel current. Flp-In CV-1
cells stably expressing the full-length KCNH2 splicing-competent con-
struct were treated with WT or modified U1 snRNA adenovirus for 48 h.
Treatment with modified U1 snRNA (3A>C/5U>A) significantly
increased Kv11.1 current compared to the WT U1 snRNA control
(Fig. 4). The maximum tail current densities in WT and modified U1
snRNA-treated cells were 7.7 ± 1.2 pA/pF and 15.5 ± 1.5 pA/pF
(P < 0.01), respectively. These patch-clamp experiments are con-
sistent with the results of immunoblot and demonstrate that modified
U1 snRNA can increase the Kv11.1 channel current.
3.5. Effect of modified U1 snRNA on Kv11.1 isoform expression in
canonical intron 9 poly(A) signal construct
We have previously shown that competition between the weak 5′
splice site and the weak poly(A) signal in intron 9 plays an important
role in regulation of the relative expression of Kv11.1a and Kv11.1a-
USO isoforms. When the weak intron 9 poly(A) signal was changed to
the strong canonical poly(A) signal, the Kv11.1a-USO isoform was
predominantly expressed (Gong et al., 2010). To test whether the
modified U1 snRNA can induce the isoform expression from Kv11.1a-
USO to Kv11.1a in the presence of a strong intron 9 poly(A) signal, we
treated CV-1 cells stably expressing the full-length KCNH2 splicing-
competent construct containing the canonical intron 9 poly(A) signal
with WT and modified U1 snRNA adenoviruses. RPA analysis showed
that in the presence of the WT U1 snRNA, Kv11.1a-USO was pre-
dominantly expressed. Treatment with modified U1 snRNA (3A>C/
5U>A) significantly increased the expression of the Kv11.1a isoform
(P < 0.001) and decreased the expression of the Kv11.1a-USO isoform
compared to WT U1 snRNA (P < 0.05) (Fig. 5). In patch clamp studies,
treatment with modified U1 snRNA significantly increased Kv11.1
current compared to the WT U1 snRNA control (Fig. 6). The maximum
tail current densities in WT and modified U1 snRNA-treated cells were
0.5 ± 0.1 pA/pF and 8.3 ± 1.3 pA/pF (P < 0.001), respectively.
These findings suggest that modified U1 snRNA is capable of upregu-
lating the Kv11.1a isoform expression in the presence of a strong intron
9 poly(A) signal. However, the maximum current density upregulated
by modified U1 snRNA is lower in the canonical intron 9 poly(A) signal
than in the weak, non-canonical intron 9 poly(A) signal (Fig. 4,
Fig. 2. Regulation of Kv11.1 isoform expression by
modified U1 snRNA in the full-length KCNH2 splicing-
competent construct. (A) The structure of the full-
length KCNH2 splicing-competent construct. (B) RPA
analysis of the effect of modified U1 snRNA on Kv11.1
isoform expression. Flp-In CV-1 cells stably expressing
the full-length KCNH2 splicing-competent construct
were treated with WT or modified U1 snRNA adeno-
virus (500 MOI) for 48 h. (C) RPA signals were quan-
tified, normalized to hygromycin resistance gene
(Hygro), and plotted as the relative expression of the
total uninfected (1a + 1a-USO) Kv11.1 mRNA (n= 3,
**P < 0.01).
Fig. 3. Regulation of Kv11.1 protein ex-
pression by modified U1 snRNA. (A) Flp-In
CV-1 cells stably expressing the full-length
KCNH2 splicing-competent construct were
treated with WT or modified U1 snRNA
adenovirus (250 or 500 MOI) for 48 h. The
expression level of hygromycin B phos-
photransferase (HPT) encoded by the hy-
gromycin B resistant gene served as a
loading control. Cell lysates were subjected
to SDS-PAGE and probed with antibodies
against the N-terminus of Kv11.1 and
against HPT. (B) The level of protein bands
was quantified, normalized to HPT, and
plotted as the relative expression of the total uninfected (1a + 1a-OSU) Kv11.1 protein (n = 3, *P < 0.05, ***P < 0.001).
Fig. 4. Effect of modified U1snRNA on Kv11.1 channel cur-
rent. (A) Representative currents recorded from Flp-In CV-1
cells stably expressing following treatment with WT or mod-
ified U1 snRNA adenovirus (500 MOI) for 48 h. (B) I–V plot of
tail current density measured at −50 mV following test vol-
tages from −70 to +50 mV for WT (triangle, n = 6) and
modified U1 snRNA (3A>C/5U>A) (circle, n= 8) adeno-
viruses.
Fig. 5. Regulation of Kv11.1 isoform expression by mod-
ified U1 snRNA in canonical poly(A) signal construct. (A)
RPA analysis of mRNA from Flp-In CV-1 cells stably ex-
pressing the full-length KCNH2 splicing-competent con-
struct containing the canonical poly(A) signal following the
treatment with WT or modified U1 snRNA adenovirus. (B)
RPA signals were quantified, normalized to hygromycin
resistance gene (Hygro), and plotted as the relative ex-
pression of the total uninfected (1a + 1a-USO) Kv11.1
mRNA (n = 3, *P < 0.05, ***P < 0.001).
P < 0.01).
4. Discussion
In the human heart, the splicing of intron 9 is inefficient with only
one-third of KCNH2 pre-mRNA being processed to the functional
Kv11.1a isoform and two-thirds of KCNH2 pre-mRNA being processed
to the C-terminally truncated, non-functional Kv11.1a-USO isoform. We
have previously demonstrated that the 5′ splice site of intron 9 deviates
from the consensus sequence, which reduces the efficiency of intron 9
splicing (Gong et al., 2010). Compared to the consensus sequence
(CAG/gtaagt), the 5′ splice site of KCNH2 intron 9 (TGG/gtatgg) differs
at four positions. Our present findings indicate that deviation from
consensus sequence weakens the complimentary base-pairing between
the 5′ splice site and the U1 snRNA, thus decreasing the efficiency of
intron 9 splicing.
The initial step of splicing process involves recognition of the 5′
splice site by U1 small nuclear ribonucleoprotein. This recognition is
mediated by complementary base-pairing between the 5′ splice site and
U1 snRNA, the RNA component of the U1 small nuclear ribonucleo-
protein. The average number of base-pairs formed by 5′ splice site and
U1 snRNA is seven, although the number varies from five to nine
(Zhuang and Weiner, 1986). The deviation of the 5′ splice site of intron
9 from the consensus sequence reduces the strength of binding between
the 5′ splice site and U1 snRNA, as U1 snRNA can presumably form only
five base-pairs with this suboptimal splice site. It has been reported that
the degree of complementarity between the 5′ splice site and U1 snRNA
is an important determinant of splicing efficiency (Zhuang and Weiner,
1986). Our results provide direct evidence that modified U1 snRNA
with increased base-pair complementarity to the 5′ splice sites of intron
9 enhances efficiency of intron 9 splicing, resulting in an increase in the
expression of the Kv11.1a isoform and a concomitant decrease in the
expression of the Kv11.1a-USO isoform. The complementary base
changes at positions 3 and 5 in the modified U1 snRNA (U1-3C/5A)
would create seven contiguous base-pairs between U1 snRNA and the 5′
splice site of intron 9 (Fig. 1B). Thus, the degree of complementarity
between the 5′ splice site and U1 snRNA plays an important role in
determining splicing efficiency of the KCNH2 intron 9.
Modification of U1 snRNA with increased complementarity to mu-
tant 5′ splice sites was originally employed to demonstrate the im-
portance of base-pair binding of U1 snRNA with 5′ splice site in the
initial step of the splicing process (Zhuang and Weiner, 1986). Modified
U1 snRNA has been used to rescue 5′ splice site disease-causing muta-
tions. Mutation-adapted U1snRNAs with complementary changes to
match mutated 5′ splice sites are able to correct splicing defects in
various cellular models of human genetic diseases (Baralle et al., 2003;
Zhang et al., 2004; Pinotti et al., 2008; Balestra et al., 2014; Glaus et al.,
2011; Schmid et al., 2011). The present findings indicate that modified
U1 snRNA can be used to increase the splicing efficiency of the
intrinsically weak KCNH2 intron 9 splice site and upregulate the ex-
pression of the functional Kv11.1a isoform. We recently identified a
KCNH2 splice site mutation that causes long QT syndrome by isoform
switch from the functional Kv11.1a isoform to the non-functional
Kv11.1a-USO isoform (Gong et al., 2014a). Modified U1 snRNA may
thus represent an ideal strategy to increase the expression of Kv11.1a
from the WT allele and overcome the isoform switch caused by the
mutant allele.
The expression of the full-length Kv11.1a isoform and the truncated
Kv11.1a-USO isoform is determined by competition between intron 9
splicing and polyadenylation at the intronic poly(A) site. The increase
in splicing efficiency by modified U1 snRNA can shift the balance to-
ward the splicing pathway, thereby leading to the upregulation of the
full-length Kv11.1a isoform. Our results also show that the modified U1
snRNA is capable of upregulating Kv11.1a isoform expression in the
presence of a strong intron 9 poly(A) signal, although the effect of
modified U1 snRNA on upregulation of the Kv11.1a isoform expression
is less than that in the presence of the native weak intron 9 poly(A)
signal. This finding suggests that relative efficiencies of intron 9 splicing
and polyadenylation play an important role in regulation of the relative
expression of the Kv11.1a and Kv11.1a-USO isoforms. Regulation of
isoform expression by the competition between splicing and intronic
polyadenylation has been reported in many genes. A well-studied ex-
ample is the regulation of the IgM heavy-chain gene, where a mem-
brane-bound form of IgM heavy-chain is produced through splicing of
intron 4 and a secreted form of IgM heavy-chain is generated by the
utilization of an intronic poly(A) site within intron 4 (Peterson and
Perry, 1989). Similarly, many receptor tyrosine kinase genes undergo
alternative processing of pre-mRNA through competing splicing and
intronic polyadenylation. Membrane-bound receptor tyrosine kinases
are generated by intron splicing and secreted isoforms are produced by
intronic polyadenylation. Inhibition of U1 snRNA binding to 5′ splice
sites by antisense oligonucleotides can activate intronic poly(A) sites,
leading to the switch from the full-length, membrane-bound isoforms to
the truncated, soluble isoforms of receptor tyrosine kinases (Vorlová
et al., 2011). Rather than increasing intronic polyadenylation by the
inhibition of splicing, our present results demonstrate that modified U1
snRNA with increased complementary binding to the weak 5′ splice
sites of KCNH2 intron 9 increases splicing efficiency and decreases in-
tronic polyadenylation. Thus, modified U1 snRNA with increased
complementarity to a weak, nonconsensus 5′ splice site may represent a
useful strategy to upregulate the expression of full-length isoforms of
other genes that are regulated by competition between splicing and
intronic polyadenylation.
In summary, our present findings show that increasing U1 snRNA
complementarity to the 5′ splice site of KCNH2 intron 9 results in an
increase in the expression of the functional Kv11.1a isoform and a
concomitant decrease in the expression of the non-functional Kv11.1a-
USO isoform. Modified U1 snRNA with increased complementarity to
Fig. 6. Effect of modified U1 snRNA on Kv11.1 channel current in
canonical poly(A) signal construct. (A) Representative currents re-
corded from Flp-In CV-1 cells stably expressing the full-length
KCNH2 splicing-competent construct containing the canonical poly
(A) signal following treatment with WT or modified U1 snRNA
adenovirus (500 MOI) for 48 h. (B) I–V plot of tail current density
measured at−50 mV following test voltages from−70 to +50 mV
for WT (triangle, n= 7) and modified U1 snRNA (3A>C/5U>A)
(circle, n = 8) adenoviruses.
the 5′ splice site of KCNH2 intron 9 may represent a novel approach to
increase Kv11.1 channel function.
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